GlassScriptPhysician profile
Lolitta E Aznaurova
NPI 1841270600
$10,570.63
in general payments reported to CMS, 2019-2025
34 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,152 · 2020: $652 · 2021: $303 · 2022: $403 · 2023: $1,963 · 2024: $2,045 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,061.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,399.02 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $1,171.80 | 2021-2025 | Vraylar |
| Lundbeck LLC | $779.63 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $602.49 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $596.78 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $573.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $568.34 | 2019-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $419.94 | 2019-2025 | Trintellix |
| Corium, LLC | $403.17 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $392.04 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.02 | 2021-2025 | Caplyta |
| Allergan, INC. | $314.04 | 2019-2020 | |
| Axsome Therapeutics, INC. | $286.34 | 2022-2025 | Auvelity, Sunosi |
| Avanir Pharmaceuticals, INC. | $230.48 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $171.40 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $164.43 | 2019-2023 | Adzenys Xr-Odt |
| Alkermes, INC. | $159.20 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $109.65 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $95.47 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $94.04 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $93.39 | 2021-2025 | Loreev Xr |
| Bausch Health US, LLC | $84.85 | 2019-2025 | Aplenzin |
| Tris Pharma INC | $77.01 | 2019-2025 | Dyanavel Xr |
| Shire North American Group INC | $76.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $72.97 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $57.24 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $39.24 | 2023-2024 | Quviviq |
| Alfasigma USA, INC. | $35.64 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $29.54 | 2020-2023 | Belsomra |
| Biogen, INC. | $20.66 | 2024 | |
| Acadia Pharmaceuticals INC | $20.21 | 2025 | Nuplazid |
| Noven Therapeutics, LLC | $15.91 | 2023 | Xelstrym |
| Eisai INC. | $15.83 | 2020 | |
| Harmony Biosciences LLC | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lolitta Aznaurova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.